Randomized coronary patency trial of doublebolus recombinant staphylokinase versus frontloaded alteplase in acute myocardial infarction

American Heart Journal

Volumn 134, Issue 2 I, 1997, Pages 213-219

  Vanderschueren, S ^a   Dens, J ^a   Kerdsinchai, P ^a   Desmet, W ^a   Vrolix, M ^a   De Man, F ^a   Van den Heuvel, P ^a   Hermans, L ^a   Collen, D ^a   Van de Werf, F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ANTIPLASMIN; ALTEPLASE; CONTRAST MEDIUM; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HEPARIN; NEUTRALIZING ANTIBODY; PLASMINOGEN; STAPHYLOKINASE; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; ALLERGIC REACTION; ANGIOCARDIOGRAPHY; ARTICLE; BOLUS INJECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY RECANALIZATION; CORONARY REPERFUSION; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030886426     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(97)70127-3     Document Type: Article

References (19)

1. G. Agnelli Rationale for bolus t-PA therapy to improve efficacy and safety Chest 97 1990 161S 167S
2. JA Purvis AJ McNeill RA Siddiqui MJ Roberts BM McClements D McEneaney Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction J Am Coll Cardiol 23 1994 6 10
3. JA. Purvis Novel and innovative dosing regimens in thrombolytic therapy for acute myocardial infarction J Thromb Thrombolysis 1 1995 145 151
4. RC. Becker Achieving optimal reperfusion without adjunctive antithrombotic therapy: novel thrombolytic dosing strategies J Thromb Thrombolysis 1 1995 269 277
5. D Collen HR. Lijnen Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood 84 1994 680 686
6. S Vanderschueren L Barrios P Kerdsinchai P Van den Heuvel L Hermans M Vrolix for the STAR Trial Group A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction Circulation 92 1995 2044 2049
7. S Vanderschueren L Stockx G Wilms H Lacroix R Verhaeghe J Vermylen Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase Circulation 92 1995 2050 2057
8. S Vanderschueren D Collen F. Van de Werf A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis Thromb Haemost 76 1996 541 544
9. The GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682
10. B Schlott M Hartmann K-H Gührs E Birch-Hirschfeld H-D Pohl S Vanderschueren High yield production and purification of recombinant staphylokinase for thrombolytic therapy Biotechnology 12 1994 185 189
11. JH Chesebro G Knatterud R Roberts J Borer LS Cohen J Dalen Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge Circulation 76 1987 142 154
12. PJ Declerck S Vanderschueren J Billiet H Moreau D. Collen Prevalence and induction of circulating antibodies against recombinant staphylokinase Thromb Haemost 71 1994 129 133
13. The GUSTO Angiographic Investigators The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction N Engl J Med 329 1993 1615 1622
14. E Braunwald The open-artery theory is alive and well—again N Engl J Med 329 1993 1650 1652
15. S Vanderschueren D. Collen Comparative effects of staphylokinase and alteplase in rabbit bleeding time models Thromb Haemost 75 1996 816 819
16. K Okada HR Lijnen H Moreau S Vanderschueren D. Collen Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator Thromb Haemost 76 1996 857 859
17. SMF Vanderschueren JM Stassen D. Collen On the immunogenicity of recombinant staphylokinase in patients and in animal models Thromb Haemost 72 1994 297 301
18. D Collen H Moreau L Stockx S. Vanderschueren Recombinant staphylokinase variants with altered immunoreactivity. II. Thrombolytic properties and antibody induction Circulation 94 1996 207 216
19. D Collen L Stockx H Lacroix R Suy S. Vanderschueren Recombinant staphylokinase variants with altered immunoreactivity. IV. Identification of variants with reduced antibody induction but intact potency Circulation 95 1997 463 472